CA2037907C - Recombinaison homologue pour cellules de donneurs universels et hotes mammaliens chimeriques - Google Patents

Recombinaison homologue pour cellules de donneurs universels et hotes mammaliens chimeriques Download PDF

Info

Publication number: CA2037907C
Authority: CA; Canada
Prior art keywords: cells; antigen; construct; loci; lesion
Prior art date: 1989-07-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002037907A

Other languages

English (en)

Other versions

CA2037907A1 (fr

Inventor

Raju S. Kucherlapati

Beverly H. Koller

Oliver. Smithies

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cell Genesys Inc

Original Assignee

Cell Genesys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-25

Filing date

1990-07-25

Publication date

2006-04-04

1990-07-25 Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc

1990-07-25 Priority claimed from PCT/US1990/004178 external-priority patent/WO1991001140A1/fr

1991-01-26 Publication of CA2037907A1 publication Critical patent/CA2037907A1/fr

2006-04-04 Application granted granted Critical

2006-04-04 Publication of CA2037907C publication Critical patent/CA2037907C/fr

2010-07-25 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000006801 homologous recombination Effects 0.000 title claims abstract description 21
238000002744 homologous recombination Methods 0.000 title claims abstract description 21
210000004027 cell Anatomy 0.000 claims abstract description 179
108090000623 proteins and genes Proteins 0.000 claims abstract description 96
239000000427 antigen Substances 0.000 claims abstract description 73
108091007433 antigens Proteins 0.000 claims abstract description 73
102000036639 antigens Human genes 0.000 claims abstract description 73
210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 18
102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims abstract description 17
108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims abstract description 17
108020004414 DNA Proteins 0.000 claims description 66
108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 51
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 51
230000003902 lesion Effects 0.000 claims description 37
210000004962 mammalian cell Anatomy 0.000 claims description 32
239000003550 marker Substances 0.000 claims description 32
238000000034 method Methods 0.000 claims description 32
210000002459 blastocyst Anatomy 0.000 claims description 28
230000014509 gene expression Effects 0.000 claims description 18
230000010354 integration Effects 0.000 claims description 18
230000009466 transformation Effects 0.000 claims description 18
210000002510 keratinocyte Anatomy 0.000 claims description 13
229930193140 Neomycin Natural products 0.000 claims description 12
229960004927 neomycin Drugs 0.000 claims description 12
238000003780 insertion Methods 0.000 claims description 10
230000037431 insertion Effects 0.000 claims description 10
230000001131 transforming effect Effects 0.000 claims description 8
108091026890 Coding region Proteins 0.000 claims description 6
210000004952 blastocoel Anatomy 0.000 claims description 5
238000003752 polymerase chain reaction Methods 0.000 claims description 5
229960004150 aciclovir Drugs 0.000 claims description 4
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 4
229960002963 ganciclovir Drugs 0.000 claims description 4
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
238000012216 screening Methods 0.000 claims description 3
108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
230000003115 biocidal effect Effects 0.000 claims description 2
210000000349 chromosome Anatomy 0.000 claims description 2
210000001339 epidermal cell Anatomy 0.000 claims description 2
230000035945 sensitivity Effects 0.000 claims description 2
241001529936 Murinae Species 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
239000002254 cytotoxic agent Substances 0.000 claims 1
231100000599 cytotoxic agent Toxicity 0.000 claims 1
230000009261 transgenic effect Effects 0.000 abstract 1
241001465754 Metazoa Species 0.000 description 26
239000012634 fragment Substances 0.000 description 25
210000001744 T-lymphocyte Anatomy 0.000 description 16
241000699670 Mus sp. Species 0.000 description 15
238000012217 deletion Methods 0.000 description 13
230000037430 deletion Effects 0.000 description 13
239000013612 plasmid Substances 0.000 description 12
230000002779 inactivation Effects 0.000 description 10
230000035772 mutation Effects 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
230000002103 transcriptional effect Effects 0.000 description 9
239000013598 vector Substances 0.000 description 9
238000011740 C57BL/6 mouse Methods 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000000523 sample Substances 0.000 description 8
230000009258 tissue cross reactivity Effects 0.000 description 8
241000484025 Cuniculus Species 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000006870 function Effects 0.000 description 7
210000000987 immune system Anatomy 0.000 description 7
239000010410 layer Substances 0.000 description 7
210000003491 skin Anatomy 0.000 description 7
108020004440 Thymidine kinase Proteins 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
102000006822 Agouti Signaling Protein Human genes 0.000 description 5
108010072151 Agouti Signaling Protein Proteins 0.000 description 5
108700028369 Alleles Proteins 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
238000004520 electroporation Methods 0.000 description 5
230000000977 initiatory effect Effects 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
230000008685 targeting Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
101150076800 B2M gene Proteins 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
108091008874 T cell receptors Proteins 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
230000000735 allogeneic effect Effects 0.000 description 4
238000010276 construction Methods 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
210000001541 thymus gland Anatomy 0.000 description 4
210000004291 uterus Anatomy 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 3
108010058597 HLA-DR Antigens Proteins 0.000 description 3
229930192392 Mitomycin Natural products 0.000 description 3
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
230000029087 digestion Effects 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
210000002257 embryonic structure Anatomy 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
210000004153 islets of langerhan Anatomy 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
230000035800 maturation Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
229960004857 mitomycin Drugs 0.000 description 3
210000003098 myoblast Anatomy 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000002207 retinal effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
238000010186 staining Methods 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102000003792 Metallothionein Human genes 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
206010028289 Muscle atrophy Diseases 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
239000005662 Paraffin oil Substances 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
241000700605 Viruses Species 0.000 description 2
208000013521 Visual disease Diseases 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000010171 animal model Methods 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
238000002659 cell therapy Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
230000007123 defense Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
210000005175 epidermal keratinocyte Anatomy 0.000 description 2
238000011010 flushing procedure Methods 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
210000004209 hair Anatomy 0.000 description 2
210000003780 hair follicle Anatomy 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
230000013011 mating Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
201000000585 muscular atrophy Diseases 0.000 description 2
229910052754 neon Inorganic materials 0.000 description 2
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
230000016087 ovulation Effects 0.000 description 2
-1 p-actin Proteins 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000006152 selective media Substances 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
238000001890 transfection Methods 0.000 description 2
208000029257 vision disease Diseases 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
108010066676 Abrin Proteins 0.000 description 1
206010068051 Chimerism Diseases 0.000 description 1
241000700112 Chinchilla Species 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
101150017040 I gene Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
241000581650 Ivesia Species 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
108700005089 MHC Class I Genes Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
206010046996 Varicose vein Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
210000001943 adrenal medulla Anatomy 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000000137 annealing Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000037308 hair color Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000008004 immune attack Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
210000003716 mesoderm Anatomy 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000009979 protective mechanism Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
210000003994 retinal ganglion cell Anatomy 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
235000012976 tarts Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
208000027185 varicose disease Diseases 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002037907A 1989-07-25 1990-07-25 Recombinaison homologue pour cellules de donneurs universels et hotes mammaliens chimeriques Expired - Lifetime CA2037907C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US38565189A	1989-07-25	1989-07-25
US385,651		1989-07-25
US43187289A	1989-11-06	1989-11-06
US431,872		1989-11-06
PCT/US1990/004178 WO1991001140A1 (fr)	1989-07-25	1990-07-25	Recombinaison homologue pour cellules donneuses universelles et hotes mammiferes chimeriques

Publications (2)

Publication Number	Publication Date
CA2037907A1 CA2037907A1 (fr)	1991-01-26
CA2037907C true CA2037907C (fr)	2006-04-04

Family

ID=36143205

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002037907A Expired - Lifetime CA2037907C (fr)	1989-07-25	1990-07-25	Recombinaison homologue pour cellules de donneurs universels et hotes mammaliens chimeriques

Country Status (1)

Country	Link
CA (1)	CA2037907C (fr)

1990
- 1990-07-25 CA CA002037907A patent/CA2037907C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2037907A1 (fr)	1991-01-26

Legal Events

Date	Code	Title	Description
1993-09-16	EEER	Examination request
2010-07-25	MKLA	Lapsed
2012-12-02	MKEC	Expiry (correction)	Effective date: 20121202

Publication	Publication Date	Title
EP0950707B1 (fr)	2009-02-18	Recombinaison homologue pour cellules donneuses universelles et hôtes mammifères chimériques
US5413923A (en)	1995-05-09	Homologous recombination for universal donor cells and chimeric mammalian hosts
US6139835A (en)	2000-10-31	Homologous recombination for allogeneic donor cells
EP0626012B1 (fr)	2003-07-09	Obtention d'homozygotes par ciblage de genes
Tybulewicz et al.	1991	Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
Zmuidzinas et al.	1995	The vav proto‐oncogene is required early in embryogenesis but not for hematopoietic development in vitro.
US7459600B2 (en)	2008-12-02	Isolation, selection and propagation of animal transgenic stem cells
Schrewe et al.	1994	Mice homozygous for a null mutation of activin βB are viable and fertile
WO1993010227A1 (fr)	1993-05-27	Animaux transgeniques exempts de prions
US5644065A (en)	1997-07-01	Genetically engineered mice containing alterations in the MHC class II genes
WO2025002401A1 (fr)	2025-01-02	Animal non humain à gène cfb modifié
US20030028911A1 (en)	2003-02-06	Transgenic mammal capable of facilitating production of donor-specific functional immunity
AU684275B2 (en)	1997-12-11	Method for defined deletions of DNA
US6642433B1 (en)	2003-11-04	Fgl-2 knockout mice
CA2037907C (fr)	2006-04-04	Recombinaison homologue pour cellules de donneurs universels et hotes mammaliens chimeriques
US5532158A (en)	1996-07-02	Interleukin-2 receptor deficient mammals
Lan et al.	2003	Generation of a germ cell nuclear factor conditional allele in mice
US6410825B1 (en)	2002-06-25	A-myb null mutant transgenic mice